PNPLA3 and metabolic dysfunction-associated steatotic liver disease: Finally, Yuya Seko et al. [33], in the largest cohort previously investigated of biopsy-proven NAFLD patients (n = 344), found that PNPLA3 genotypes were not associated with baseline eGFR nor with eGFR decline and the development of CKD at the end of follow-up.